DPTs at tumor sites secrete more IL-10, IDO, and TGFβ and express higher levels of immune checkpoints PD-1, LAG-3, and TIM-3 than Tregs, CD4+ T cells and CD8+ T cells. The gene discussed is HAVCR2; the disease is neoplasm.